Drugs / Brelovitug
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07454837 | Feb 2026 → Aug 2027 expected | hepatitis D virus infection | Mirum Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06907290 | Mar 2025 → May 2029 expected | hepatitis D virus infection | Mirum Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07298330 | Jan → Aug 2026 overdue | hepatitis D virus infection | Mirum Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07200908 | Aug 2025 → Jun 2027 expected | hepatitis D virus infection | Mirum Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-09-28 | Mirum Pharmaceuticals, Inc. | Results Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus mirumpharma.com ↗
Phase 3 primary endpoint (virologic response and ALT normalization) achieved in both dose arms at Week 24 |
| 2026-05-30 | Mirum Pharmaceuticals, Inc. | Results Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026 mirumpharma.com ↗
Late-breaking Phase 2b AZURE-1 results demonstrate efficacy and safety of brelovitug for the treatment of chronic hepatitis delta virus (HDV), including in patients with advanced disease |
| 2026-05-21 | Mirum Pharmaceuticals, Inc. | Results Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026 mirumpharma.com ↗
Late-breaking Phase 2b AZURE-1 results demonstrate efficacy and safety of brelovitug for the treatment of chronic hepatitis delta virus (HDV) |
| 2026-04-27 | Mirum Pharmaceuticals, Inc. | Results Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus mirumpharma.com ↗
At Week 24, treatment with brelovitug demonstrated robust antiviral activity across both dose groups. |
All press releases naming this drug 6 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Brelovitug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07454837 ↗ |
| Known as | BJT-778 | “This is a Phase 2b/3 study designed to evaluate the safety and efficacy of chronic treatment with brelovitug (a.k.a BJT-778; BTG) for chronic hepatitis delta virus (HDV) infection.” NCT06907290 ↗ |
| Known as | BTG | “This is a Phase 2b/3 study designed to evaluate the safety and efficacy of chronic treatment with brelovitug (a.k.a BJT-778; BTG) for chronic hepatitis delta virus (HDV) infection.” NCT06907290 ↗ |
| Route | Subcutaneous | “Route of administration- Subcutaneous Injection” NCT06907290 ↗ |